0
0
Read Time:2 Minute, 37 Second
Mumbai, India – 8 May 2025 – Sudarshan Pharma Industries Ltd (BSE: 543828), a rapidly growing player in the pharmaceutical and specialty chemicals sector, is actively seeking to acquire or partner with a modern Chemical or Active Pharmaceutical Ingredient (API) manufacturing facility as part of its aggressive expansion and integration strategy.
The company is calling for proposals from facility owners, industrial developers, and consultants for manufacturing units that fulfill the following specifications:
- Construction Year: Built in 2020 or later, incorporating modern infrastructure and automation.
- Facility Type: Chemical or API manufacturing unit, capable of supporting scalable industrial production.
- Compliance: Preferably GMP-compliant, with relevant national and international regulatory approvals.
- Preferred Locations: Saykha, Dahej, Vizag, or any other prominent industrial belt with robust logistical and utility infrastructure.
- Ownership: The facility should be available for outright acquisition.
“Sudarshan Pharma is on a transformative path, and acquiring a state-of-the-art facility is pivotal to meeting our next phase of operational scale and international compliance,” said Mr. Sachin Mehta, Director of Sudarshan Pharma. “We’re looking to fast-track this initiative and are open to strategic discussions with serious sellers and collaborators.”
The company is particularly interested in facilities that can provide:
- Full plant layout details
- Information on production capacities and installed equipment
- Regulatory compliance documentation
- Transparent commercial terms for sale or partnership
Strong Financial Momentum
Sudarshan Pharma Industries Ltd is listed on the Bombay Stock Exchange (BSE) under the ticker BOM:543828. As of May 2, 2025, the company has achieved a market capitalization of ₹6.42 billion, reflecting sustained investor confidence and strong business performance. This remarkable growth is a testament to SPIL’s focused strategy, robust execution, and rising relevance in the global pharmaceutical and specialty chemicals landscape.
The expansion initiative is led by a seasoned leadership team:
- Mr. Hemal Mehta, Founder and Managing Director, brings over two decades of experience in pharmaceutical marketing, regulatory strategy, and global sourcing. His visionary approach and understanding of global pharma trends have positioned Sudarshan Pharma as a dynamic force in the industry.
- Mr. Sachin Mehta, Director, plays a key role in driving operational efficiency, new business ventures, and investor relations. Known for his pragmatic execution and entrepreneurial insight, he is spearheading the company’s strategic partnerships and acquisitions.
Call for Proposals
Parties with suitable facilities are encouraged to submit detailed proposals, including:
- Plant blueprints and layout
- Capacity details and current operational status
- Compliance certificates (GMP, FDA, etc.)
- Pricing and transaction structure
Contact Information
For proposals and inquiries, please contact:
📞 Phone
- Sachin Mehta – +91 88501 18323
- Hemal Mehta – +91 92234 32107
- Manish Chaudhary – +91 80971 49641
- Vidhi Bosamia – +91 82915 06229
🌐 Website: www.sudarshanpharma.com
About Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd is a BSE-listed pharmaceutical and specialty chemicals company with a global footprint. The company specializes in manufacturing APIs, intermediates, specialty chemicals, and finished formulations. With over two decades of industry leadership and a rapidly growing market presence, SPIL is trusted by clients in India, Europe, the Middle East, and Southeast Asia. Its robust R&D, customer-centric model, and high regulatory standards make it a reliable partner for healthcare and industrial needs.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
